430 related articles for article (PubMed ID: 35032495)
21. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders.
Scuderi C; Filippis DD; Iuvone T; Blasio A; Steardo A; Esposito G
Phytother Res; 2009 May; 23(5):597-602. PubMed ID: 18844286
[TBL] [Abstract][Full Text] [Related]
22. Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE; Szaflarski JP
Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
[TBL] [Abstract][Full Text] [Related]
23. Epilepsy and cannabidiol: a guide to treatment.
Arzimanoglou A; Brandl U; Cross JH; Gil-Nagel A; Lagae L; Landmark CJ; Specchio N; Nabbout R; Thiele EA; Gubbay O; The Cannabinoids International Experts Panel ;
Epileptic Disord; 2020 Feb; 22(1):1-14. PubMed ID: 32096470
[TBL] [Abstract][Full Text] [Related]
24. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study.
Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109
[TBL] [Abstract][Full Text] [Related]
25. Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence.
Prud'homme M; Cata R; Jutras-Aswad D
Subst Abuse; 2015; 9():33-8. PubMed ID: 26056464
[TBL] [Abstract][Full Text] [Related]
26. Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?
Crippa JAS; Hallak JEC; Zuardi AW; Guimarães FS; Tumas V; Dos Santos RG
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):121-133. PubMed ID: 30706171
[TBL] [Abstract][Full Text] [Related]
27. An Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects.
Martinez Naya N; Kelly J; Corna G; Golino M; Polizio AH; Abbate A; Toldo S; Mezzaroma E
Molecules; 2024 Jan; 29(2):. PubMed ID: 38257386
[TBL] [Abstract][Full Text] [Related]
28. Cannabidiol efficiently suppressed the acquisition and expression of methamphetamine-induced conditioned place preference in the rat.
Anooshe M; Nouri K; Karimi-Haghighi S; Mousavi Z; Haghparast A
Behav Brain Res; 2021 Apr; 404():113158. PubMed ID: 33571569
[TBL] [Abstract][Full Text] [Related]
29. Cannabidiol and brain function: current knowledge and future perspectives.
Schouten M; Dalle S; Mantini D; Koppo K
Front Pharmacol; 2023; 14():1328885. PubMed ID: 38288087
[TBL] [Abstract][Full Text] [Related]
30. Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle.
Gonzalez-Cuevas G; Martin-Fardon R; Kerr TM; Stouffer DG; Parsons LH; Hammell DC; Banks SL; Stinchcomb AL; Weiss F
Neuropsychopharmacology; 2018 Sep; 43(10):2036-2045. PubMed ID: 29686308
[TBL] [Abstract][Full Text] [Related]
31. Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder.
Lees R; Hines LA; Hindocha C; Baio G; Shaban NDC; Stothart G; Mofeez A; Morgan CJA; Curran HV; Freeman TP
Psychopharmacology (Berl); 2023 Feb; 240(2):337-346. PubMed ID: 36598543
[TBL] [Abstract][Full Text] [Related]
32. The effects of acute cannabidiol on cerebral blood flow and its relationship to memory: An arterial spin labelling magnetic resonance imaging study.
Bloomfield MAP; Green SF; Hindocha C; Yamamori Y; Yim JLL; Jones APM; Walker HR; Tokarczuk P; Statton B; Howes OD; Curran HV; Freeman TP
J Psychopharmacol; 2020 Sep; 34(9):981-989. PubMed ID: 32762272
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview.
Mandolini GM; Lazzaretti M; Pigoni A; Oldani L; Delvecchio G; Brambilla P
Epidemiol Psychiatr Sci; 2018 Aug; 27(4):327-335. PubMed ID: 29789034
[TBL] [Abstract][Full Text] [Related]
34. Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance.
Martini S; Gemma A; Ferrari M; Cosentino M; Marino F
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834537
[TBL] [Abstract][Full Text] [Related]
35. Effects of cannabidiol on alcohol-related outcomes: A review of preclinical and human research.
Nona CN; Hendershot CS; Le Foll B
Exp Clin Psychopharmacol; 2019 Aug; 27(4):359-369. PubMed ID: 31120285
[TBL] [Abstract][Full Text] [Related]
36. Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative.
Silva NR; Gomes FV; Fonseca MD; Mechoulam R; Breuer A; Cunha TM; Guimarães FS
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):369-377. PubMed ID: 28720466
[TBL] [Abstract][Full Text] [Related]
37. Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses.
Umpierrez LS; Costa PA; Michelutti EA; Baracz SJ; Sauer M; Turner AJ; Everett NA; Arnold JC; McGregor IS; Cornish JL
Psychopharmacology (Berl); 2022 May; 239(5):1593-1603. PubMed ID: 35435462
[TBL] [Abstract][Full Text] [Related]
38. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
[TBL] [Abstract][Full Text] [Related]
39. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.
Crippa JA; Guimarães FS; Campos AC; Zuardi AW
Front Immunol; 2018; 9():2009. PubMed ID: 30298064
[No Abstract] [Full Text] [Related]
40. Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines.
Arellano AL; Papaseit E; Romaguera A; Torrens M; Farré M
CNS Neurol Disord Drug Targets; 2017; 16(5):554-566. PubMed ID: 28412920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
